In vivo mechanisms of Mycobacterium tuberculosis control and susceptibility

结核分枝杆菌控制和易感性的体内机制

• 批准号: 10389976
• 负责人: Dmitri I Kotov
• 金额: $ 7.23万
• 依托单位: UNIVERSITY OF CALIFORNIA BERKELEY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10389976
• 关键词: Anti-Bacterial Agents; Antibiotic Therapy; Autoimmune Diseases; Bacteria; Biological Response Modifiers; Bone Marrow; Cause of Death; Cells; Cessation of life; Chimera organism; Chronic; Clinical Trials; Communication; Data; Data Set; Development; Disease; Environment; Gene Expression; Genes; Goals; Granulocyte-Macrophage Colony-Stimulating Factor; Growth; Health; Hematopoietic; Heterogeneity; Host Defense; Human; Immune; Immune response; Immunologic Factors; Immunosuppression; Incidence; Individual; Infection; Infection Control; Inflammatory; Interleukin-1; Interleukin-1 Receptors; Interleukin-18; Knowledge; Laboratories; Lung; Mediating; Mouse Strains; Multi-Drug Resistance; Mus; Mycobacterium tuberculosis; Neutrophilia; Pathway interactions; Population; Predisposition; Production; Research Design; Role; Series; Signal Transduction; T cell response; TNF gene; Testing; Therapeutic; Time; Tuberculosis; Vaccines; acute infection; anakinra; antagonist; cytokine; enhancing factor; experimental study; in vivo; in vivo evaluation; inflammatory milieu; inhibitor; insight; interleukin-22; macrophage; mortality; neutrophil; novel; novel strategies; pathogen; programmed cell death protein 1; protective effect; protective factors; receptor; resistant strain; response; sensor; single cell analysis; single-cell RNA sequencing; success; vaccine efficacy; vaccine strategy

Project Summary Mycobacterium tuberculosis (Mtb) infects the lungs causing 1.6 million deaths a year. The only vaccine approved for tuberculosis has limited efficacy. Additionally, antibiotic treatment requires six months, but can require two or more years for multi-drug resistant strains that are becoming more prevalent. Therefore, development of a host-directed therapeutic strategy that directly targets the Mtb reservoir would dramatically impact human health. I propose to identify novel innate immune factors that protect against Mtb infection in vivo, which could be the basis of such a therapeutic approach. Specific Aims: During Mtb infection, inflammatory cytokines like IL-1 stimulate non-infected cells to produce factors that enhance anti-bacterial activity of Mtb-bearing cells. While IL-1 is critical for protection against Mtb, its mechanism of action is unknown. Aim 1) We have identified IL-1 sensing cells in Mtb-infected lungs and IL-1-induced genes expressed by these cells. I will test whether natural killer T 17 cells, one of the IL-1 sensing populations, provides protection against Mtb. Additionally, I will determine which IL-1-induced genes act directly on Mtb infected macrophages in vivo to confer the protective effect of IL-1. Aim 2) Neutrophils are detrimental in Mtb- susceptible mouse strains and neutrophilia positively correlates with bacterial burden and mortality in humans. However, it is unclear how neutrophils interfere with the host response to Mtb. We have previously shown that IL-1 receptor antagonist (IL-1Ra) is an immunosuppressive molecule that limits Mtb control in a susceptible mouse strain. As IL-1Ra is highly expressed by neutrophils, I will determine whether neutrophils inhibit the protective response against Mtb through their production of IL-1Ra and whether this immunosuppressive function is conserved across multiple Mtb susceptible strains. Additionally, I will determine whether neutrophils exploit other immunosuppressive pathways, like IL-18 signaling inhibition and PD-1, to hinder the productive immune response to Mtb. Study Design: I will define how communication between non-infected and infected cells leads to control of tuberculosis infection by generating mixed bone marrow chimeras. These experiments will test the in vivo relevance of IL-1-driven gene expression for candidates identified in our single cell RNA- sequencing dataset of Mtb-infected lungs. Additionally, I will leverage our single cell RNA-sequencing dataset to determine how neutrophils inhibit control of the infection in Mtb-sensitive mouse strains. Potential Impact: The identification of protective and inhibitory regulators of Mtb control can serve as the basis for host-directed therapies to treat Mtb infection, which will be a major advance for the field.

项目摘要 结核分枝杆菌（Mtb）感染肺部，每年造成160万人死亡。唯一的疫苗 批准用于结核病的药物疗效有限。此外，抗生素治疗需要六个月，但可以 需要两年或更长的时间来应对越来越普遍的多药耐药菌株。因此，我们认为， 开发一种直接靶向结核分枝杆菌储库的宿主导向治疗策略， 影响人类健康。我建议鉴定新的先天性免疫因子，以防止结核杆菌感染， 体内，这可能是这种治疗方法的基础。具体目的：在结核分枝杆菌感染期间， 炎性细胞因子如IL-1刺激未感染的细胞产生增强抗细菌的因子， 携带结核杆菌的细胞的活性。虽然IL-1对于预防Mtb至关重要，但其作用机制是 未知目的：1）鉴定结核分枝杆菌感染肺组织中的IL-1敏感细胞和IL-1诱导基因 由这些细胞表达。我将测试自然杀伤T 17细胞，IL-1感应群体之一， 提供针对Mtb的保护。此外，我将确定哪些IL-1诱导的基因直接作用于结核分枝杆菌， 感染的巨噬细胞，以赋予IL-1的保护作用。目的2）嗜中性粒细胞在Mtb中是有害的。 易感小鼠品系和嗜热菌与人类的细菌负荷和死亡率呈正相关。 然而，目前尚不清楚中性粒细胞如何干扰宿主对结核分枝杆菌的反应。我们之前已经证明， IL-1受体拮抗剂（IL-1 Ra）是一种免疫抑制分子，在易感人群中限制Mtb控制。 小鼠品系。由于中性粒细胞高度表达IL-1 Ra，我将确定中性粒细胞是否抑制IL-1 Ra的表达。 通过产生IL-1 Ra对Mtb的保护性反应，以及这种免疫抑制是否 功能在多种Mtb易感菌株中保守。另外，我将确定中性粒细胞 利用其他免疫抑制途径，如IL-18信号传导抑制和PD-1，以阻碍生产性 对结核病的免疫应答研究设计：我将定义非感染者和感染者之间的交流 细胞通过产生混合骨髓嵌合体来控制结核病感染。这些实验 将测试IL-1驱动的基因表达在我们的单细胞RNA中鉴定的候选者的体内相关性， 结核分枝杆菌感染肺的测序数据集。此外，我将利用我们的单细胞RNA测序数据集， 以确定嗜中性粒细胞如何抑制结核分枝杆菌敏感小鼠品系中的感染控制。潜在影响： Mtb控制的保护性和抑制性调节剂的鉴定可以作为宿主定向的基础。 治疗结核分枝杆菌感染的新疗法，这将是该领域的一个重大进展。